Analyst consensus: bullish or bearish?
Analysts rate Sysmex Corporation Buy (bullish), based on 14 analysts. Average price target: JP¥2,139.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- ShareXTKSEDINET:S100Z5XU
- ShareXTKSEDINET:S100Y8R5
- 82.5% of flowShareXTKSEDINET:S100Y42S
- ShareXTKSEDINET:S100Y5P5
- ShareXTKSEDINET:S100X85I
- 17.5% of flowShareXTKSEDINET:S100TB3T
- ShareXTKSEDINET:S100T7CD
- ShareXTKSEDINET:S100SPXA
- ShareXTKSEDINET:S100Q2LF
9 of 9 declarations
About Sysmex Corporation
Sysmex Corporation (シスメックス株式会社) has few filings (10), but its 4 filers hold 27.3% of its capital, a high share. This Japanese health care company is valued at JPY 1,181.6 billion. The filings are published from March 18, 2022 to October 5, 2026, with no purchase or sale classed.
BlackRock Japan Co., Ltd. lodges 5 filings and Nakatani Co.,Ltd. 3; Baillie Gifford & Co and Sysmex Corporation itself have 1 each. All four are Large shareholders.
Read moreShow less
The calendar: 2022, 2023 and 2025 have 1 filing each, 2024 has 3 and 2026 has 4. Five filings, half of the record, fall within the last twelve months. Six days at the median pass between a transaction and its publication, the most recent transaction dating from September 30, 2026. The recorded sector is health care. Baillie Gifford & Co has a single filing in the record, and the first publication dates from March 18, 2022.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
